NGM Biopharmaceuticals's Return On Capital Employed Insights
Portfolio Pulse from Benzinga Insights
NGM Biopharmaceuticals reported Q1 sales of $2.25 million and a loss of $47.65 million, a 30.77% decrease from last quarter. The company posted a negative ROCE of -0.22%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.58, missing analyst predictions of $-0.52.
May 18, 2023 | 2:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NGM Biopharmaceuticals reported a negative ROCE of -0.22% and missed analyst predictions for Q1 earnings per share.
The negative ROCE of -0.22% indicates inefficient capital allocation, which may negatively impact the company's long-term success. Additionally, missing analyst predictions for Q1 earnings per share could lead to a short-term decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100